Arthneeti
All Q2 FY26 results →
V.

Viatris Inc.

Q2 FY26Pharmaceuticals

Viatris Inc. Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹16
Market cap₹18.8K Cr
P/E6.1
Updated29 May 2026
Read4 min read

What the Q2 FY26 call signalled

1 of 3 strong

RevenueSlow growth
MarginMargins steady
CapexCapex planned

The short version

- Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026. - Viatris delivered 3% revenue growth and 10% adjusted EBITDA growth in Q1 2026, showing strong momentum.

From Viatris Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Slow growth
  • Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026.
  • Growth is expected to ramp up into 2027-2029, supported by multiple pipeline catalysts and product launches.
  • Strong momentum in Greater China with 18% year-over-year growth, driven by cardiovascular portfolio and e-commerce expansion.
  • Continued growth expected from launches in the U.S., including fast-acting meloxicam and XULANE LO contraceptive patch.
  • Generic portfolio progress with FDA approvals and launches planned (e.g., generic Abilify Maintena in the U.S. by year's end).
  • Innovative drugs selatogrel and cenerimod Phase III programs on track, with potential longer-term growth impact.

2 more points from Viatris Inc.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Viatris Inc. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • The company is making significant investments to expand manufacturing capacity, particularly to support sustainable growth for products like Creon.
  • They continue to invest in their commercial platforms, notably in China, including e-commerce capabilities which have shown strong sales growth.
  • Capital allocation remains disciplined, balancing shareholder returns (dividends and share repurchases) with strategic investments in the business to support sustainable growth.
  • Business development focuses on in-market, accretive assets aligned with company capabilities to strengthen long-term growth.
  • The company is on track to deliver cost savings from an enterprise-wide strategic review and is reinvesting some of these savings to support future growth.

2 more points from Viatris Inc.'s call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Viatris Inc. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company highlights strong commercial execution, particularly in Greater China and Japan, indicating a robust demand environment.
  • Several key product launches and regulatory approvals are expected in 2026, including:
  • Fast-acting meloxicam (NDA accepted, approval expected by year-end).
  • Low-dose estrogen transdermal contraceptive patch (XULANE LO) with expected PDUFA date by July 30, 2026.
  • Phentolamine ophthalmic solution with an expected PDUFA date of October 17, 2026.
  • Japan market includes recent approval for EFFEXOR in generalized anxiety disorder and upcoming approvals for pitolisant and Nefecon.

2 more points from Viatris Inc.'s call on order book

Create a free account to keep reading this call

Continue your research

Others in Pharmaceuticals this season

  • Elanco Animal Health Incorporated (Q2 FY26)

    Elanco Animal Health Incorporated Q2 FY26 quarterly results analysis. Elanco expects continued momentum with high single-digit to low double-digit growth in U.S

  • Axsome Therapeutics, Inc. (Q2 FY26)

    Axsome Therapeutics, Inc. Q2 FY26 quarterly results analysis. AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from

  • Jazz Pharmaceuticals plc (Q2 FY26)

    Jazz Pharmaceuticals plc Q2 FY26 quarterly results analysis. Epidiolex: Encouraged by strong first-quarter performance ($250 million; 15% revenue growth, 16% vo

  • Royalty Pharma plc (Q2 FY26)

    Royalty Pharma plc Q2 FY26 quarterly results analysis. Royalty Pharma expects strong low-volatility top and bottom line growth through 2030 and beyond, driven b

Compare:vs AstraZeneca PLCvs Johnson & Johnsonvs Novartis AG

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Viatris Inc. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Viatris Inc. Q2 FY26 results?

- Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026. - Viatris delivered 3% revenue growth and 10% adjusted EBITDA growth in Q1 2026, showing strong momentum.

What is Viatris Inc. share price analysis?

Viatris Inc. currently shows a neutral. The stock trades at a P/E of 6.1 with a market cap of $18,761. Investors should review the full earnings analysis for detailed insights.

Is Viatris Inc. planning capital expenditure?

- The company is making significant investments to expand manufacturing capacity, particularly to support sustainable growth for products like Creon.

Keep Viatris Inc. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.